Reckitt Benckiser CEO says Adams acquisition may lead to U.S. markets
BERKSHIRE, England While there are no immediate plans to bring Boots Healthcare International across the pond to American markets, Adams Respiratory was acquired, in part, to afford Reckitt Benckiser the ability to do that, Bart Becht, Reckitt Benckiser chief executive officer, explained to analysts during a conference call last week.
“[Adams] was very strategic for us as a company because it’s one of the few targets that allows us to get a healthcare infrastructure in the U.S., which we don’t have. And to build that organically is extremely difficult and costly,” Becht said. “Financially it makes sense simply because the very high growth that is in that business. Clearly if this would have been an ordinary low-growth healthcare business, we would have bid a very different amount of money or we would have walked away from it. … It’s a high growth business.”
Reckitt Benckiser officially closed the Adams deal Jan. 30 in a deal valued at approximately $2.3 billion. As a result of the merger, Adams shares will be delisted and cease to trade on the NASDAQ Global Select Market.
Isma Benattia named Wyeth Consumer Healthcare head of global R&D
MADISON, N.J. Wyeth Consumer Healthcare announced that Isma Benattia has been named executive vice president of Global Research and Development, effective immediately.
In her new role, Benattia will be in charge of bringing new products to market and managing regulatory necessities regarding Wyeth’s over-the-counter products.
Benattia has served at Wyeth Pharmaceuticals since 2003, where she most recently was vice president in charge of Global Labeling. She previously held the position of executive medical director of neuroscience, where she played a leading role in managing scientific and regulatory issues involving Effexor, Wyeth’s second largest brand in terms of global revenue.
Prior to joining Wyeth, Benattia led global clinical programs for major products at Pfizer and Eli Lilly. She holds Master’s degrees in Pharmacology and Psychotropic Drugs; Methodology of Clinical Research and Medical and Marketing Management.
Study shows Relacore may reduce acne flare-ups
NEW YORK Carter Reed on Friday released studies that suggests its dietary supplement diet aid Relacore may be useful in reducing acne flare-ups.
“One of the reasons Relacore has been so successful is because people buy it along with other diet pills or to use in conjunction with any sensible diet and exercise plan,” stated Gina Daines, Carter-Reed’s director of marketing. “Now when it comes to acne, we’re seeing the same phenomenon—those who buy popular anti-acne treatments, like Proactive, are picking up a bottle of Relacore to expand and complete their anti-acne regimen, using Relacore to help prevent the stress-related increase, duration, frequency and severity of acne flare-ups.”